Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Combination cancer therapy achieved by prodrug-activating enzymes and cytokines
July 14th, 2006
According to recent research from Taiwan published in the journal Bioconjugate Chemistry, combination cancer therapy is achieved by hapten-targeted prodrug-activating enzymes and cytokines. "Combination therapy can help overcome limitations in the treatment of heterogeneous tumors. In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells," wrote K.H. Chuang and colleagues, Kaohsiung Medical University. "Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo....
Source: Genomics & Genetics Weekly (2006-07-14)
|
